Identifying candidates with desirable metabolism and safety profiles during the drug discovery phase is essential for increasing the likelihood of clinical success. Eurofins Discovery’s Drug Candidate Selection Panels provide a cost-effective, comprehensive selection of key in vitro ADME, Toxicology, and Safety Pharmacology assays and in vivo non-GLP DMPK and Safety models that can be utilized at various phases of development to quickly and efficiently progress lead candidates further into development.
| Available Drug Candidate Selection Panels | ||||
|---|---|---|---|---|
| Tier 1 ADME Panel
10 Day Turnaround |
Tier 2 ADME Panel
20 Day Turnaround |
In Vitro Toxicology Panel
15 Day Turnaround |
In Vitro Safety Pharmacology Panels | In Vivo DMPK and Safety Models |
| Quickly profile key compound in vitro properties essential for selecting candidates with desirable pharmacokinetic (PK) profiles for later stages of drug development with our Tier 1 ADME Panel.
This panel of 8 assays can be used to quickly and efficiently determine drug candidate ADME properties including;
View/Order Panel:
|
Generate data necessary to progress lead compounds into clinical development with our Tier 2 ADME panel of IND-enabling assays.
This panel of 41 IND-enabling assays providing comprehensive drug metabolism, transporter, and Drug-Drug Interaction data that is necessary to progress lead compounds into clinical development:
This panel contains items G232, G234, G230, G345, G206, 4482, 4483, and G346 (ref# P376) |
Access greater predictability of potential compound-mediated toxicities with this in vitro toxicology panel that brings together a wide range of key toxicity assays in a single panel.
This panel of 24 toxicology assays can be utilized to effectively de-risk drug candidates for a broad range of potential adverse effects including:
This panel contains items G175, G344, 533, PCiPACore, G202, and 4573 (ref# PSC375) |
Utilize industry-leading SafetyScreen™ binding panels and SAFETYscan® functional panels to enable early identification of potential undesirable off-target effects to reduce drug attrition.
Our broad selection of in vitro Safety Pharmacology panels enable testing candidates in both functional and binding assays to assess and mitigate off-target liabilities that are strongly associated with clinical adverse drug reactions.
|
Understand the physicochemical properties and risk profile of drug candidate(s) with non-GLP in vivo DMPK & Safety models offered by Pharmacology Discovery Services, a partner lab of Eurofins Discovery.
|
| View Panel | View Panel | View Panel | Learn More | Learn More |
